Trial Profile
A Phase 2 Study of Tarloxotinib (TH-4000) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 16 Jan 2023
Price :
$35
*
At a glance
- Drugs Tarloxotinib (Primary)
- Indications Head and neck cancer; Oropharyngeal cancer; Skin cancer; Squamous cell cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors Rain Oncology; Threshold Pharmaceuticals
- 29 Dec 2022 According to Rain Oncology media release, Rain Therapeutics has changed its name to Rain Oncology.
- 18 Apr 2022 Results published in the Investigational New Drugs
- 29 Sep 2016 Status changed from recruiting to discontinued, considering the the totality of the clinical data obtained in the interim analysis which do not justify further evaluation, according to a Threshold Pharmaceuticals media release.